TARA

Protara Therapeutics Inc

Feb 26 • 04:00PM ET

5.77

-0.19 -3.19 %

Healthcare • Biotechnology • USA • NASD

Feb 24, 8:30 PMInterim Phase 2 trial data showing weak 12-month durability triggered 26% plunge.

Peers: BMRN CRSP NTLA SRPT RARE QURE BLUE SGMO VYGR PGEN

| Held by: VTI IWM VXF IWN VTWO IWC AVSC DFAS VFMO SBIO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.44	Insider Own	9.32%	Shs Outstand	51.63M	Perf Week	-19.30%
Market Cap	297.91M	Forward P/E	-	EPS next Y	-1.45	Insider Trans	0.00%	Shs Float	46.82M	Perf Month	-20.63%
Enterprise Value	168.90M	PEG	-	EPS next Q	-0.33	Inst Own	71.20%	Short Float	7.07%	Perf Quarter	-21.71%
Income	-52.90M	P/S	-	EPS this Y	41.28%	Inst Trans	41.42%	Short Ratio	2.86	Perf Half Y	84.35%
Sales	0.00M	P/B	1.68	EPS next Y	-13.79%	ROA	-44.32%	Short Interest	3.31M	Perf YTD	8.26%
Book/sh	3.43	P/C	2.25	EPS next 5Y	8.10%	ROE	-49.42%	52W High	7.82 -26.21%	Perf Year	64.86%
Cash/sh	2.57	P/FCF	-	EPS past 3/5Y	19.85% 55.31%	ROIC	-39.27%	52W Low	2.77 108.30%	Perf 3Y	70.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.44% 7.53%	Perf 5Y	-66.45%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	48.84%	Oper. Margin	-	ATR (14)	0.57	Perf 10Y	-97.50%
Dividend Ex-Date	-	Quick Ratio	13.69	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.31	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.69	EPS Q/Q	37.58%	SMA20	-12.58%	Beta	1.41	Target Price	25.50
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-3.56%	Rel Volume	1.29	Prev Close	5.96
Employees	33	LT Debt/Eq	0.02	Earnings	Nov 10 BMO	SMA200	27.50%	Avg Volume	1.15M	Price	5.77
IPO	Oct 22, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	19.27% -	Trades		Volume	1,472,313	Change	-3.19%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Piper Sandler	Overweight	$24
Apr-16-25	Initiated	Scotiabank	Sector Outperform	$12
Mar-14-25	Initiated	Cantor Fitzgerald	Overweight
Jul-10-23	Resumed	Guggenheim	Buy	$22
Jun-04-21	Initiated	H.C. Wainwright	Buy	$40
Feb-17-21	Initiated	Oppenheimer	Outperform	$43
Oct-19-20	Initiated	Cowen	Outperform	$50
Jul-29-20	Initiated	Guggenheim	Buy	$50

Feb-25-26 03:12AM	Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU (MarketBeat) +8.96%
Feb-24-26 07:41AM	Protara's Experimental Bladder Cancer Drug Shows Encouraging Results (Benzinga) -26.38%
Feb-23-26 05:05PM	TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) +8.63%
Feb-19-26 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.20%
Feb-02-26 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Jan-22-26 08:00AM	Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium (GlobeNewswire)
Jan-12-26 07:00AM	Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones (GlobeNewswire) -8.87%
Jan-07-26 08:00AM	Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +11.13%
08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support (GlobeNewswire)
Jan-05-26 08:00AM	Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Dec-08-25 04:05PM	Protara Announces Closing of $75 Million Public Offering (GlobeNewswire)
Dec-04-25 10:03PM	Protara Announces Pricing of $75 Million Public Offering (GlobeNewswire) -18.78%
04:15PM	Protara Announces Proposed Public Offering (GlobeNewswire)
Dec-03-25 08:00AM	Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients (GlobeNewswire) +9.32%
Dec-01-25 04:15PM	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients on Wednesday, December 3, 2025 (GlobeNewswire) -8.67% -7.72%
08:00AM	Loading…
Nov-19-25 08:00AM	Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Nov-18-25 04:30PM	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 (GlobeNewswire) +21.18%
Nov-17-25 08:00AM	Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-10-25 08:06AM	Protara Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +5.59%
08:00AM	Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 04:05PM	Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace (GlobeNewswire) -9.28%
Oct-01-25 04:03PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-21-25 06:15AM	Analysts Predict Up to 840% Jump for These 2 Strong Buy Penny Stocks (TipRanks)
Sep-02-25 04:05PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-25 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-25 06:14PM	Protara Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-25 04:08PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-25 04:12PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.59%
Jun-30-25 08:00AM	Protara Therapeutics Announces Addition to the Russell 3000 Index (GlobeNewswire) +5.21%
04:04PM	Loading…
Jun-02-25 04:04PM	Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer (GlobeNewswire) +8.55%
May-13-25 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-25 08:00AM	Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-01-25 04:09PM	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-25 10:00AM	Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC (GlobeNewswire)
Apr-23-25 08:00AM	Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 (GlobeNewswire) +6.60%
Apr-15-25 04:13PM	Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer (GlobeNewswire)
Apr-10-25 04:05PM	Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting (GlobeNewswire) -6.25%
Apr-09-25 12:00PM	Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade (Zacks) +6.67%
Mar-28-25 05:10PM	Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results (Seeking Alpha) -6.99%
Mar-19-25 08:00AM	Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support (GlobeNewswire) +8.78%
Mar-05-25 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.04%
Feb-26-25 08:00AM	Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-05-25 08:00AM	Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Protara Highlights Recent Updates and Anticipated 2025 Milestones (GlobeNewswire)
Jan-08-25 08:00AM	Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 04:05PM	Protara Announces Closing of $100 Million Public Offering (GlobeNewswire)
Dec-09-24 11:35PM	Protara Announces Pricing of $100 Million Public Offering (GlobeNewswire) +12.86% -6.30%
04:01PM	Protara Announces Proposed Public Offering (GlobeNewswire)
Dec-05-24 07:00AM	Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC (GlobeNewswire) +70.06%
Dec-03-24 08:00AM	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024 (GlobeNewswire) +11.46%
Nov-15-24 05:52PM	Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire) -6.48%
Nov-12-24 08:00AM	Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-24 08:00AM	Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire) -6.13%
Oct-21-24 08:00AM	Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support (GlobeNewswire) +5.24%
Sep-09-24 08:05AM	Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support (GlobeNewswire)
Sep-03-24 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-06-24 08:00AM	Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jun-24-24 05:06PM	Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.83%
May-21-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-02-24 12:54PM	TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-12-24 09:55AM	Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-05-24 08:04AM	Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing (GlobeNewswire) -9.70%
08:02AM	Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition (GlobeNewswire)
08:00AM	Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC (GlobeNewswire)
Mar-13-24 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 08:00AM	Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -7.45%
Jan-31-24 07:30AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-30-23 08:30AM	Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-23 09:43AM	Protara Therapeutics Inc (TARA) Announces Q3 2023 Financial Results (GuruFocus.com) +11.57%
08:00AM	Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-23-23 08:00AM	Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Sep-20-23 08:30AM	Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ (GlobeNewswire)
Sep-05-23 07:30AM	Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 08:00AM	Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-15-23 08:00AM	Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ (GlobeNewswire)
May-04-23 08:00AM	Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update (GlobeNewswire)
May-02-23 08:00AM	Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations (GlobeNewswire)
Apr-28-23 08:00AM	Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development (GlobeNewswire)
Mar-08-23 08:00AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-23 08:00AM	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +10.76%
Feb-02-23 08:00AM	Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day (GlobeNewswire)
Jan-30-23 08:00AM	Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer (GlobeNewswire)
Dec-01-22 08:00AM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology (GlobeNewswire)
Nov-03-22 08:00AM	Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Oct-24-22 08:35AM	Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-06-22 08:00AM	Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 08:00AM	Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Jun-21-22 08:00AM	Protara Therapeutics Announces Departure of Chief Financial Officer (GlobeNewswire)
May-26-22 05:11PM	Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +5.44%
May-17-22 08:00AM	Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:32AM	Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely? (Simply Wall St.)
May-12-22 08:00AM	Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations (GlobeNewswire)
May-05-22 08:00AM	Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview (GlobeNewswire)
Apr-11-22 09:55AM	Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect? (Zacks) -6.17%
Mar-24-22 08:00AM	Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Mar-23-22 10:00AM	Does Protara Therapeutics (TARA) Have the Potential to Rally 688% as Wall Street Analysts Expect? (Zacks) +5.06%
Mar-09-22 07:30AM	Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview (GlobeNewswire)

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
667, L.P.	Former Affiliate	Feb 25 '26	Proposed Sale	5.81	78,716	457,046		Feb 25 07:58 PM
Baker Brothers Life Sciences,	Former Affiliate	Feb 25 '26	Proposed Sale	5.81	947,479	5,501,316		Feb 25 07:57 PM
667, L.P.	Former Affiliate	Feb 24 '26	Proposed Sale	6.04	26,755	161,584		Feb 24 09:13 PM
Baker Brothers Life Sciences,	Former Affiliate	Feb 24 '26	Proposed Sale	6.04	322,039	1,944,922		Feb 24 09:11 PM
Levy Richard S	Director	May 14 '25	Buy	3.19	20,000	63,800	51,000	May 16 04:05 PM
Zummo Jacqueline	Chf Scientific Operations Off	Mar 26 '25	Sale	4.53	21,224	96,145	98,861	Mar 28 04:12 PM
Zummo Jacqueline	Officer	Mar 26 '25	Proposed Sale	4.55	21,224	96,569		Mar 26 11:17 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TARA

Protara Therapeutics Inc

Upgrade your FINVIZ experience